← Eichor
Condition: Pancreatic Cancer Synced from ClinicalTrials.gov · July 27, 2026

Recruiting studies: Pancreatic Cancer

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.
Phase 1/Phase 2 · 10 location(s) · Eikon Therapeutics · NCT06907043A Noninvasive and Screening miRNA Signature for Gastrointestinal Cancer
Phase N/A · 1 location(s) · City of Hope Medical Center · NCT07224750Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable
Phase 2 · 1 location(s) · Emory University · NCT06423326ONT01 and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma
Phase 1/Phase 2 · 1 location(s) · Washington University School of Medicine · NCT06904378Computed Tomography in Diagnosing Patients With Pancreatic or Hepatobiliary Cancer
NA · 1 location(s) · M.D. Anderson Cancer Center · NCT02361320An Open-label, Multicenter, Phase II Clinical Study to Evaluate HRS-7058 in Patients With Pancreatic Cancer
Phase 2 · 2 location(s) · Shandong Suncadia Medicine Co., Ltd. · NCT07589569A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors
Phase 1 · 9 location(s) · PAQ Therapeutics, Inc. · NCT07300150Evaluation of PET Probe [68Ga]CBP8 in the Detection of Radiation Induced Tissue Injury
Phase 2 · 1 location(s) · Massachusetts General Hospital · NCT04485286Evaluating Obesity-Mediated Mechanisms of Pancreatic Carcinogenesis in Minority Populations
Phase N/A · 2 location(s) · H. Lee Moffitt Cancer Center and Research Institute · NCT05687188Pilot Study of Pancreatic Cancer Screening
Phase N/A · 1 location(s) · University of California, San Francisco · NCT05058846Gemcitabine and Leflunomide in Patients With Advanced Unresectable Pancreatic Cancer
Phase 1 · 1 location(s) · City of Hope Medical Center · NCT06454383First-line Regimen With QL1706 Plus Chemo ± Bev in PDAC Patients
Phase 2 · 1 location(s) · Fudan University · NCT06313970A Study to Determine the Effect of CT3001 in Patients With Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Crossignal Therapeutics, Inc. · NCT06598007Surufatinib Plus Gemcitabine and Nab-paclitaxel vs. Gemcitabine Plus Nab-paclitaxel in Neoadjuvant Therapy for High - Ri
Phase 3 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT07436741Pancreatic Cancer and Diabetes Mellitus
Phase N/A · 1 location(s) · Shanghai Changzheng Hospital · NCT06585072HRS-4642 Combination With Other Antitumor Therapies in Patients With Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Shanghai Hengrui Pharmaceutical Co., Ltd. · NCT07296341A Pilot Study to Assess the Clinical Utility of PYLARIFY PET-CT for Detecting Metastasis in Pancreatic Cancer, Hepatocel
Phase 1 · 1 location(s) · M.D. Anderson Cancer Center · NCT05394259A Phase II Study Evaluating BMS-986504 in MTAP-deleted Pancreatic Cancer
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT07283705A Study of Nuzefatide Pevedotin (BT5528) in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
Phase 2 · 3 location(s) · BicycleTx Limited · NCT07450859A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and
Phase 2/Phase 3 · 2 location(s) · Hutchmed · NCT06361888Cryoablation Combined With the Dual-Function Antibody PD-1/CTLA-4 for the Treatment of LAPC Following Failure of First-L
Phase 2 · 1 location(s) · Ruijin Hospital · NCT07306286A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Phase 1 · 62 location(s) · Seagen, a wholly owned subsidiary of Pfizer · NCT05208762The Characteristics of Oral Microbiota in Chronic Pancreatitis and Autoimmune Pancreatitis
Phase N/A · 1 location(s) · Ruijin Hospital · NCT07015580An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancr
Phase 3 · 2 location(s) · Jiangsu HengRui Medicine Co., Ltd. · NCT05884255Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors
Phase 1 · 1 location(s) · Monopar Therapeutics · NCT06337084A Prospective Study of Liquid Biopsy for Pancreatic Cancer Early Detection
Phase N/A · 3 location(s) · Fudan University · NCT06166147A New Clinical Pathway for Personalized Management of Borderline Resectable and Locally Advanced Pancreatic Cancer
Phase N/A · 5 location(s) · Oslo University Hospital · NCT06944587A Study on the Prevalence of Clinically Useful Mutations in Solid Tumor Characterized by Next Generation Sequencing Meth
Phase N/A · 1 location(s) · Centro di Riferimento Oncologico - Aviano · NCT06028724LRAMPS Versus LDP in Selected Early-stage Left-sided Pancreatic Cancer
NA · 1 location(s) · Fudan University · NCT05939063A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
Phase 1/Phase 2 · 60 location(s) · Bayer · NCT06914128
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.